XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
  Hypertension
  CAD
  Myocardial Infarction
  CHF
  Clinical Trials
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Cardiology Channel
subscribe to Cardiology newsletter

Latest Research : Cardiology

   DISCUSS   |   EMAIL   |   PRINT
A percutaneous ventricular assist device provides reliable temporary circulatory support for critically ill patients
Jan 22, 2006, 22:15, Reviewed by: Dr. Rashmi Yadav

"The TandemHeart System's superior flow rate, minimal complications, and the speed with which it can be delivered to critically ill patients without traumatic surgery will continue to increase this device's presence in heart centers in this country and abroad."

 
CardiacAssist, Inc., a Pittsburgh- based medical device company that develops, manufactures and markets cardiac assist devices, has announced the completion of the 500th worldwide procedure to help heart failure patients survive heart attacks, high-risk procedures and other cardiac interventions without undergoing major surgery.

Four prestigious heart centers across the U.S. helped CardiacAssist surpass the 500th procedure for its TandemHeart PTVA System, a percutaneous left ventricular assist device (LVAD) with FDA 510(k) clearance for short-term use.

"Working together with regional heart centers around the nation, we've been able to reach a new level of acceptance," said Michael Garippa, president and CEO of CardiacAssist. "The TandemHeart System's superior flow rate, minimal complications, and the speed with which it can be delivered to critically ill patients without traumatic surgery will continue to increase this device's presence in heart centers in this country and abroad."

The centers performing the procedures during the week of January 8-January 14, 2006 include:


- University of Wisconsin Hospital and Clinics, Madison, Wis.;
- Medical City Heart, Dallas, Texas;
- Deborah Heart & Lung Center, Browns Mills, N.J.; and
- University of Washington Regional Heart Center, Seattle, Wash.

The TandemHeart System helps restore blood circulation through a cardiac catheterization procedure in as little as 30 minutes. The resulting increase in blood flow -- up to five liters per minute -- helps to save vital organs and gives damaged hearts a chance to heal when patients experience acute, life-threatening heart conditions.

The TandemHeart System is the only percutaneous ventricular assist device cleared by the FDA for sale in the U.S. The TandemHeart System is fully reimbursed by Medicare under existing DRG codes. The device can be placed rapidly in the cath lab or operating room, providing effective, reliable temporary circulatory support for critically ill patients.

To date, more than 500 uses of the device in 28 countries at 60 different facilities by 100 different physicians have been performed.

 

- CardiacAssist, Inc.
 

http://www.cardiacassist.com/

 
Subscribe to Cardiology Newsletter
E-mail Address:

 

About CardiacAssist

Founded in 1996, CardiacAssist, Inc. is a privately held, Pittsburgh-based medical device company that develops, manufactures and markets innovative products designed to provide cardiologists and cardiac surgeons with minimally invasive solutions for treating weakened and failing hearts. Its vision is to help advance the treatment of heart disease by bridging gaps in current treatment methodologies.

This press release may contain certain forward-looking statements that relate to CardiacAssist's future business and financial performance. Such statements are subject to a number of risks and uncertainties that may cause the actual events or future results to differ from those discussed herein.


Media Contact: Sarah Lowery
Armada Medical Marketing
303-623-1190 x239
[email protected]

Monica Bush
CardiacAssist, Inc.
412-963-7770 x247
[email protected]



Related Cardiology News

Seven-point system gauges seriousness of heart failure in elderly
Uric acid levels closely related to hypertension in Blacks
American College of Cardiology announces new initiative to improve safety for patients with Acute Coronary Syndromes
Is TROPHY misleading?
Fortified orange juice decreases not only cholesterol but also CRP
Heart Disease: Blame it on genes!
Famotidine may help to slow progression of chronic heart failure
Atherothrombotic disease is not just a 'western' problem
Changing normal heart cells into pacemakers
Ilk gene underlies heart failure


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us